China is waging war on Alzheimer’s. What can its approach teach the rest of the world?
Article Meta data
Article Date: 24 February 2026
Article URL: https://www.nature.com/articles/d41586-026-00564-2
Article Image: https://media.nature.com/w767/magazine-assets/d41586-026-00564-2/d41586-026-00564-2_52093946.jpg
Summary
China is preparing for a sharp rise in Alzheimer’s and related dementias as its population ages. The government has launched funding programmes, recruited returning scientists and ramped up clinical trials. Research covers drug candidates (including ones derived from traditional Chinese medicine), biomarker and genetic studies to detect disease earlier, and experimental surgical approaches intended to clear brain waste-removal pathways. Clinical activity has surged — from single-digit trials a few years ago to over a hundred by 2024 — and large local centres are receiving substantial regional investment. Alongside genuine progress, concerns remain about unproven surgical procedures being offered prematurely and the need for rigorous trials and regulation.
Key Points
- China already houses nearly 30% of the world’s people with dementia and projections put cases in the tens of millions by 2050.
- The government has prioritised Alzheimer’s: funding, national targets (to 2030), and talent recruitment — especially returnees from abroad.
- Clinical research is expanding rapidly: the number of Alzheimer’s trials listed in China rose from 9 in 2021 to 107 by 2024.
- Drug programmes include TrkB-activating candidates such as BrAD-R13 and compounds from traditional Chinese medicine (for example NBP from Chinese celery) that show promising preclinical and early clinical signals.
- Researchers are investing in biomarkers and genetics to detect disease earlier and understand mechanisms specific to Chinese populations.
- Novel surgical approaches (LVA, cervical shunting/CSULS) aim to improve the brain’s glymphatic clearance but are controversial; LVA was banned for Alzheimer’s use by China’s National Health Commission pending clinical evidence.
- Despite faster progress and growing quality, China’s Alzheimer’s research funding still trails the US in absolute terms; collaboration and rigorous trials remain crucial.
Context and relevance
The story matters because China’s scale and central coordination create both opportunity and risk. Large patient populations, targeted funding, and active recruitment of overseas talent can accelerate trials and biomarker discovery — potentially shifting global research priorities and diversifying study cohorts. At the same time, rapid adoption of unproven interventions illustrates the need for robust regulation and clear evidence standards. Other countries can learn from China’s focus on early detection, infrastructure investment and talent repatriation — while also heeding the warning that speed must not outpace rigorous evaluation.
Author’s take
Punchy: This is a national-scale pivot towards dementia science. China isn’t just adding funds — it’s building centres, running more trials and pushing unconventional ideas (including TCM-derived drugs and surgeries). The net result could be useful new therapies and data — provided investigators keep standards high.
Why should I read this?
Because China is gearing up for a dementia tsunami and doing it fast. If you follow Alzheimer’s research, public-health planning or innovation policy, this piece saves you time: it pulls together where the money, trials and bold ideas are headed — and flags what’s promising versus what needs stricter proof. Short version: watch the drugs and biomarkers, be wary of the hype around surgery.